GlassScriptPhysician profile
Tejas D Desai
NPI 1902981533
$8,595.89
in general payments reported to CMS, 2019-2025
30 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,197 · 2020: $492 · 2021: $1,028 · 2022: $1,585 · 2023: $2,190 · 2024: $957 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,121 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,121.02 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,001.03 | 2019-2025 | |
| Abbvie INC. | $1,423.85 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,119.29 | 2021-2025 | Tremfya, Stelara, Remicade |
| Genzyme Corporation | $998.10 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $953.54 | 2021-2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $328.24 | 2022-2025 | Odomzo, Blu-U |
| Revance Therapeutics, INC. | $218.45 | 2024-2025 | Daxxify |
| Merz North America, INC. | $168.02 | 2019-2022 | |
| Boston Scientific Corporation | $131.25 | 2021 | |
| Strata Skin Sciences, INC. | $128.02 | 2019-2024 | Xtrac |
| Janssen Scientific Affairs, LLC | $125.00 | 2021 | |
| Paratek Pharmaceuticals, INC. | $115.22 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $111.73 | 2023-2024 | Sotyktu |
| Genentech USA, INC. | $99.00 | 2019 | |
| Amgen INC. | $96.64 | 2023-2025 | Otezla, Otezla |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $86.79 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $79.70 | 2024-2025 | Nemluvio, Aklief |
| Sanofi-Aventis U.S. LLC | $72.00 | 2019 | |
| Pfizer INC. | $57.10 | 2021-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $43.88 | 2022-2023 | Valchlor |
| Dermavant Sciences, INC. | $40.21 | 2023-2024 | Vtama |
| Almirall LLC | $37.51 | 2023 | Seysara |
| Leo Pharma INC. | $29.25 | 2022 | |
| Organon LLC | $27.09 | 2025 | |
| Incyte Corporation | $24.38 | 2022 | |
| Ucb, INC. | $21.98 | 2023 | Cimzia |
| Biofrontera INC. | $20.86 | 2025 | |
| Allergan, INC. | $18.31 | 2022 | |
| Botanix Sb INC | $16.59 | 2025 | Sofdra |
| Journey Medical Corporation | $2.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejas Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.